[1]
Nyamweya S, Hegedus A, Jaye A, Rowland-Jones S, Flanagan KL, Macallan DC. Comparing HIV-1 and HIV-2 infection: Lessons for viral immunopathogenesis. Reviews in medical virology. 2013 Jul:23(4):221-40. doi: 10.1002/rmv.1739. Epub 2013 Feb 26
[PubMed PMID: 23444290]
[2]
Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2011 Mar 15:52(6):780-7. doi: 10.1093/cid/ciq248. Epub
[PubMed PMID: 21367732]
[3]
Gottlieb GS, Raugi DN, Smith RA. 90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. The lancet. HIV. 2018 Jul:5(7):e390-e399. doi: 10.1016/S2352-3018(18)30094-8. Epub
[PubMed PMID: 30052509]
[4]
Peruski AH, Wesolowski LG, Delaney KP, Chavez PR, Owen SM, Granade TC, Sullivan V, Switzer WM, Dong X, Brooks JT, Joyce MP. Trends in HIV-2 Diagnoses and Use of the HIV-1/HIV-2 Differentiation Test - United States, 2010-2017. MMWR. Morbidity and mortality weekly report. 2020 Jan 24:69(3):63-66. doi: 10.15585/mmwr.mm6903a2. Epub 2020 Jan 24
[PubMed PMID: 31971928]
[5]
Visseaux B, Damond F, Matheron S, Descamps D, Charpentier C. Hiv-2 molecular epidemiology. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases. 2016 Dec:46():233-240. doi: 10.1016/j.meegid.2016.08.010. Epub 2016 Aug 12
[PubMed PMID: 27530215]
[6]
Gottlieb GS, Sow PS, Hawes SE, Ndoye I, Coll-Seck AM, Curlin ME, Critchlow CW, Kiviat NB, Mullins JI. Molecular epidemiology of dual HIV-1/HIV-2 seropositive adults from Senegal, West Africa. AIDS research and human retroviruses. 2003 Jul:19(7):575-84
[PubMed PMID: 12908935]
[7]
Lemey P, Pybus OG, Wang B, Saksena NK, Salemi M, Vandamme AM. Tracing the origin and history of the HIV-2 epidemic. Proceedings of the National Academy of Sciences of the United States of America. 2003 May 27:100(11):6588-92
[PubMed PMID: 12743376]
[9]
Kloser PC, Mangia AJ, Leonard J, Lombardo JM, Michaels J, Denny TN, Sharer L, Sathe S, Weiss SH, Schable C. HIV-2-associated AIDS in the United States. The first case. Archives of internal medicine. 1989 Aug:149(8):1875-7
[PubMed PMID: 2764658]
Level 3 (low-level) evidence
[10]
de Silva TI, van Tienen C, Onyango C, Jabang A, Vincent T, Loeff MF, Coutinho RA, Jaye A, Rowland-Jones S, Whittle H, Cotten M, Hué S. Population dynamics of HIV-2 in rural West Africa: comparison with HIV-1 and ongoing transmission at the heart of the epidemic. AIDS (London, England). 2013 Jan 2:27(1):125-34. doi: 10.1097/QAD.0b013e32835ab12c. Epub
[PubMed PMID: 23032414]
[11]
Mendoza C, Lozano AB, Caballero E, Cabezas T, Ramos JM, Soriano V. Antiretroviral Therapy for HIV-2 Infection in Non-Endemic Regions. AIDS reviews. 2020:22(1):44-56. doi: 10.24875/AIDSRev.M20000029. Epub
[PubMed PMID: 32167506]
[12]
Gottlieb GS. Changing HIV epidemics: what HIV-2 can teach us about ending HIV-1. AIDS (London, England). 2013 Jan 2:27(1):135-7. doi: 10.1097/QAD.0b013e32835a11a4. Epub
[PubMed PMID: 23221427]
[13]
Carvalho AC, Valadas E, França L, Carvalho C, Aleixo MJ, Mendez J, Marques R, Sarmento A, Doroana M, Antunes F, Branco T, Aguas M, Sarmento E Castro R, Lazarus JV, Barros H. Population mobility and the changing epidemics of HIV-2 in Portugal. HIV medicine. 2012 Apr:13(4):219-25. doi: 10.1111/j.1468-1293.2011.00963.x. Epub 2011 Dec 4
[PubMed PMID: 22136745]
[14]
García-Deltoro M. Rapid Initiation of Antiretroviral Therapy after HIV Diagnosis. AIDS reviews. 2019:21(2):55-64. doi: 10.24875/AIDSRev.M19000027. Epub
[PubMed PMID: 31332395]
[15]
de Silva TI, Cotten M, Rowland-Jones SL. HIV-2: the forgotten AIDS virus. Trends in microbiology. 2008 Dec:16(12):588-95. doi: 10.1016/j.tim.2008.09.003. Epub 2008 Oct 27
[PubMed PMID: 18964021]
[16]
De Cock KM, Adjorlolo G, Ekpini E, Sibailly T, Kouadio J, Maran M, Brattegaard K, Vetter KM, Doorly R, Gayle HD. Epidemiology and transmission of HIV-2. Why there is no HIV-2 pandemic. JAMA. 1993 Nov 3:270(17):2083-6
[PubMed PMID: 8147962]
[17]
Remy G. [HIV-2 infection in the world. A geographical perspective]. Sante (Montrouge, France). 1998 Nov-Dec:8(6):440-6
[PubMed PMID: 10064918]
Level 3 (low-level) evidence
[18]
Centers for Disease Control and Prevention (CDC). HIV-2 Infection Surveillance--United States, 1987-2009. MMWR. Morbidity and mortality weekly report. 2011 Jul 29:60(29):985-8
[PubMed PMID: 21796096]
[19]
Poulsen AG, Kvinesdal B, Aaby P, Mølbak K, Frederiksen K, Dias F, Lauritzen E. Prevalence of and mortality from human immunodeficiency virus type 2 in Bissau, West Africa. Lancet (London, England). 1989 Apr 15:1(8642):827-31
[PubMed PMID: 2564911]
[20]
Wilkins A, Ricard D, Todd J, Whittle H, Dias F, Paulo Da Silva A. The epidemiology of HIV infection in a rural area of Guinea-Bissau. AIDS (London, England). 1993 Aug:7(8):1119-22
[PubMed PMID: 8397950]
[21]
Tienen Cv, van der Loeff MS, Zaman SM, Vincent T, Sarge-Njie R, Peterson I, Leligdowicz A, Jaye A, Rowland-Jones S, Aaby P, Whittle H. Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. Journal of acquired immune deficiency syndromes (1999). 2010 Apr:53(5):640-7. doi: 10.1097/QAI.0b013e3181bf1a25. Epub
[PubMed PMID: 19841588]
[22]
Larsen O, da Silva Z, Sandström A, Andersen PK, Andersson S, Poulsen AG, Melbye M, Dias F, Nauclér A, Aaby P. Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau. AIDS (London, England). 1998 Sep 10:12(13):1707-14
[PubMed PMID: 9764792]
[23]
da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, Andersson S, Aaby P. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing? AIDS (London, England). 2008 Jun 19:22(10):1195-202. doi: 10.1097/QAD.0b013e328300a33d. Epub
[PubMed PMID: 18525265]
[24]
Schmidt WP, Van Der Loeff MS, Aaby P, Whittle H, Bakker R, Buckner M, Dias F, White RG. Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau. Epidemiology and infection. 2008 Apr:136(4):551-61
[PubMed PMID: 17559692]
[25]
Alabi AS, Jaffar S, Ariyoshi K, Blanchard T, Schim van der Loeff M, Awasana AA, Corrah T, Sabally S, Sarge-Njie R, Cham-Jallow F, Jaye A, Berry N, Whittle H. Plasma viral load, CD4 cell percentage, HLA and survival of HIV-1, HIV-2, and dually infected Gambian patients. AIDS (London, England). 2003 Jul 4:17(10):1513-20
[PubMed PMID: 12824789]
[26]
Berry N, Ariyoshi K, Jaffar S, Sabally S, Corrah T, Tedder R, Whittle H. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. Journal of human virology. 1998 Nov-Dec:1(7):457-68
[PubMed PMID: 10195267]
[27]
Esbjörnsson J, Månsson F, Kvist A, da Silva ZJ, Andersson S, Fenyö EM, Isberg PE, Biague AJ, Lindman J, Palm AA, Rowland-Jones SL, Jansson M, Medstrand P, Norrgren H, Sweden and Guinea-Bissau Cohort Research Group. Long-term follow-up of HIV-2-related AIDS and mortality in Guinea-Bissau: a prospective open cohort study. The lancet. HIV. 2018 Nov 1:():. pii: S2352-3018(18)30254-6. doi: 10.1016/S2352-3018(18)30254-6. Epub 2018 Nov 1
[PubMed PMID: 30392769]
[28]
Andersson S, Norrgren H, da Silva Z, Biague A, Bamba S, Kwok S, Christopherson C, Biberfeld G, Albert J. Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection. Archives of internal medicine. 2000 Nov 27:160(21):3286-93
[PubMed PMID: 11088091]
[29]
Marlink R, Kanki P, Thior I, Travers K, Eisen G, Siby T, Traore I, Hsieh CC, Dia MC, Gueye EH. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science (New York, N.Y.). 1994 Sep 9:265(5178):1587-90
[PubMed PMID: 7915856]
[30]
Schim van der Loeff MF, Jaffar S, Aveika AA, Sabally S, Corrah T, Harding E, Alabi A, Bayang A, Ariyoshi K, Whittle HC. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS (London, England). 2002 Sep 6:16(13):1775-83
[PubMed PMID: 12218389]
[31]
Adjorlolo-Johnson G, De Cock KM, Ekpini E, Vetter KM, Sibailly T, Brattegaard K, Yavo D, Doorly R, Whitaker JP, Kestens L. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA. 1994 Aug 10:272(6):462-6
[PubMed PMID: 8040982]
[32]
Burgard M, Jasseron C, Matheron S, Damond F, Hamrene K, Blanche S, Faye A, Rouzioux C, Warszawski J, Mandelbro L, ANRS French Perinatal Cohort EPF-CO1. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2010 Oct 1:51(7):833-43. doi: 10.1086/656284. Epub
[PubMed PMID: 20804413]
[33]
Ghys PD, Fransen K, Diallo MO, Ettiègne-Traoré V, Coulibaly IM, Yeboué KM, Kalish ML, Maurice C, Whitaker JP, Greenberg AE, Laga M. The associations between cervicovaginal HIV shedding, sexually transmitted diseases and immunosuppression in female sex workers in Abidjan, Côte d'Ivoire. AIDS (London, England). 1997 Oct:11(12):F85-93
[PubMed PMID: 9342059]
[34]
Esbjörnsson J, Månsson F, Kvist A, Isberg PE, Nowroozalizadeh S, Biague AJ, da Silva ZJ, Jansson M, Fenyö EM, Norrgren H, Medstrand P. Inhibition of HIV-1 disease progression by contemporaneous HIV-2 infection. The New England journal of medicine. 2012 Jul 19:367(3):224-32. doi: 10.1056/NEJMoa1113244. Epub
[PubMed PMID: 22808957]
[35]
Prince PD, Matser A, van Tienen C, Whittle HC, Schim van der Loeff MF. Mortality rates in people dually infected with HIV-1/2 and those infected with either HIV-1 or HIV-2: a systematic review and meta-analysis. AIDS (London, England). 2014 Feb 20:28(4):549-58. doi: 10.1097/01.SPC.0000432532.87841.78. Epub
[PubMed PMID: 23921613]
Level 1 (high-level) evidence
[36]
Sørensen A, Jespersen S, Katzenstein TL, Medina C, Té Dda S, Correira FG, Hviid CJ, Laursen AL, Wejse C. Clinical presentation and opportunistic infections in HIV-1, HIV-2 and HIV-1/2 dual seropositive patients in Guinea-Bissau. Infectious diseases (London, England). 2016 Aug:48(8):604-11. doi: 10.1080/23744235.2016.1180708. Epub 2016 May 10
[PubMed PMID: 27163507]
[37]
van der Sande MA, Schim van der Loeff MF, Bennett RC, Dowling M, Aveika AA, Togun TO, Sabally S, Jeffries D, Adegbola RA, Sarge-Njie R, Jaye A, Corrah T, McConkey S, Whittle HC. Incidence of tuberculosis and survival after its diagnosis in patients infected with HIV-1 and HIV-2. AIDS (London, England). 2004 Sep 24:18(14):1933-41
[PubMed PMID: 15353979]
[38]
Lucas SB, Hounnou A, Peacock C, Beaumel A, Djomand G, N'Gbichi JM, Yeboue K, Hondé M, Diomande M, Giordano C. The mortality and pathology of HIV infection in a west African city. AIDS (London, England). 1993 Dec:7(12):1569-79
[PubMed PMID: 7904450]
[39]
Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S, Emerson C, Fidler S, Fisher M, Horne R, Khoo S, Leen C, Mackie N, Marshall N, Monteiro F, Nelson M, Orkin C, Palfreeman A, Pett S, Phillips A, Post F, Pozniak A, Reeves I, Sabin C, Trevelion R, Walsh J, Wilkins E, Williams I, Winston A. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV medicine. 2016 Aug:17 Suppl 4():s2-s104. doi: 10.1111/hiv.12426. Epub
[PubMed PMID: 27568911]
[40]
Khan S, Haragsim L, Laszik ZG. HIV-associated nephropathy. Advances in chronic kidney disease. 2006 Jul:13(3):307-13
[PubMed PMID: 16815235]
Level 3 (low-level) evidence
[41]
Izzedine H, Damond F, Brocheriou I, Ghosn J, Lassal H, Deray G. HIV-2 infection and HIV-associated nephropathy. AIDS (London, England). 2006 Apr 4:20(6):949-50
[PubMed PMID: 16549986]
[42]
Centers for Disease Control and Prevention (CDC). National HIV Testing Day and new testing recommendations. MMWR. Morbidity and mortality weekly report. 2014 Jun 27:63(25):537
[PubMed PMID: 25095328]
[43]
Chang M, Wong AJ, Raugi DN, Smith RA, Seilie AM, Ortega JP, Bogusz KM, Sall F, Ba S, Seydi M, Gottlieb GS, Coombs RW. Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm. Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 2017 Jan:86():56-61. doi: 10.1016/j.jcv.2016.11.011. Epub 2016 Nov 23
[PubMed PMID: 27951466]
Level 2 (mid-level) evidence
[44]
Popper SJ, Sarr AD, Travers KU, Guèye-Ndiaye A, Mboup S, Essex ME, Kanki PJ. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. The Journal of infectious diseases. 1999 Oct:180(4):1116-21
[PubMed PMID: 10479138]
[45]
Jones J, Sullivan PS, Curran JW. Progress in the HIV epidemic: Identifying goals and measuring success. PLoS medicine. 2019 Jan:16(1):e1002729. doi: 10.1371/journal.pmed.1002729. Epub 2019 Jan 18
[PubMed PMID: 30657770]
[46]
Gottlieb GS, Eholié SP, Nkengasong JN, Jallow S, Rowland-Jones S, Whittle HC, Sow PS. A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa. AIDS (London, England). 2008 Oct 18:22(16):2069-72; discussion 2073-4. doi: 10.1097/QAD.0b013e32830edd44. Epub
[PubMed PMID: 18832869]
Level 1 (high-level) evidence
[47]
Matheron S, Descamps D, Gallien S, Besseghir A, Sellier P, Blum L, Mortier E, Charpentier C, Tubiana R, Damond F, Peytavin G, Ponscarme D, Collin F, Brun-Vezinet F, Chene G, France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group. First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Sep 28:67(8):1161-1167. doi: 10.1093/cid/ciy245. Epub
[PubMed PMID: 29590335]
[48]
Ba S, Raugi DN, Smith RA, Sall F, Faye K, Hawes SE, Sow PS, Seydi M, Gottlieb GS, University of Washington–Dakar HIV-2 Study Group. A Trial of a Single-tablet Regimen of Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Disoproxil Fumarate for the Initial Treatment of Human Immunodeficiency Virus Type 2 Infection in a Resource-limited Setting: 48-Week Results From Senegal, West Africa. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Oct 30:67(10):1588-1594. doi: 10.1093/cid/ciy324. Epub
[PubMed PMID: 29672676]
[49]
Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S, ANRS CO5 HIV-2 Cohort Study Group. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients. AIDS (London, England). 2009 Jun 1:23(9):1171-3. doi: 10.1097/QAD.0b013e32832949f0. Epub
[PubMed PMID: 19349850]
[50]
INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. The New England journal of medicine. 2015 Aug 27:373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20
[PubMed PMID: 26192873]
[51]
Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel. JAMA. 2016 Jul 12:316(2):191-210. doi: 10.1001/jama.2016.8900. Epub
[PubMed PMID: 27404187]
[52]
Shah SS, Fine SM, Vail RM, McGowan JP, Merrick ST, Radix AE, Hoffmann CJ, Gonzalez CJ. Diagnosis and Management of HIV-2 in Adults. 2022 Aug:():
[PubMed PMID: 32573998]
[53]
Charpentier C, Visseaux B, Bénard A, Peytavin G, Damond F, Roy C, Taieb A, Chêne G, Matheron S, Brun-Vézinet F, Descamps D, ANRS CO5 HIV-2 Cohort. Transmitted drug resistance in French HIV-2-infected patients. AIDS (London, England). 2013 Jun 19:27(10):1671-4. doi: 10.1097/QAD.0b013e32836207f3. Epub
[PubMed PMID: 23595155]
[54]
Gottlieb GS, Raugi DN, Smith RA, University of Washington-Dakar HIV-2 Study Group. HIV Drug Resistance. The New England journal of medicine. 2018 Mar 1:378(9):874-5. doi: 10.1056/NEJMc1716089. Epub
[PubMed PMID: 29504389]
[55]
Laville P, Fartek S, Cerisier N, Flatters D, Petitjean M, Regad L. Impacts of drug resistance mutations on the structural asymmetry of the HIV-2 protease. BMC molecular and cell biology. 2020 Jun 23:21(1):46. doi: 10.1186/s12860-020-00290-1. Epub 2020 Jun 23
[PubMed PMID: 32576133]
[56]
Martinez-Steele E, Awasana AA, Corrah T, Sabally S, van der Sande M, Jaye A, Togun T, Sarge-Njie R, McConkey SJ, Whittle H, Schim van der Loeff MF. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS (London, England). 2007 Jan 30:21(3):317-24
[PubMed PMID: 17255738]
[57]
Tchounga B, Ekouevi DK, Balestre E, Dabis F. Mortality and survival patterns of people living with HIV-2. Current opinion in HIV and AIDS. 2016 Sep:11(5):537-544
[PubMed PMID: 27254747]
Level 3 (low-level) evidence
[58]
Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antiviral therapy. 2004 Feb:9(1):57-65
[PubMed PMID: 15040537]
[59]
Smith RA, Wu VH, Zavala CG, Raugi DN, Ba S, Seydi M, Gottlieb GS, University of Washington-Dakar HIV-2 Study Group. In Vitro Antiviral Activity of Cabotegravir against HIV-2. Antimicrobial agents and chemotherapy. 2018 Oct:62(10):. doi: 10.1128/AAC.01299-18. Epub 2018 Sep 24
[PubMed PMID: 30012774]
[60]
Ojikutu B, Holman J, Kunches L, Landers S, Perlmutter D, Ward M, Fant G, Hirschhorn L. Interdisciplinary HIV care in a changing healthcare environment in the USA. AIDS care. 2014:26(6):731-5. doi: 10.1080/09540121.2013.855299. Epub 2013 Nov 6
[PubMed PMID: 24191727]
[61]
Doshi RK, Milberg J, Isenberg D, Matthews T, Malitz F, Matosky M, Trent-Adams S, Parham Hopson D, Cheever LW. High rates of retention and viral suppression in the US HIV safety net system: HIV care continuum in the Ryan White HIV/AIDS Program, 2011. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2015 Jan 1:60(1):117-25. doi: 10.1093/cid/ciu722. Epub 2014 Sep 15
[PubMed PMID: 25225233]